A primer for academic entrepreneurs on academic-industrial partnerships

被引:5
作者
Hait, William N. [1 ]
Stoffels, Paulus [2 ,3 ]
机构
[1] Johnson & Johnson, External Innovat, Global External Innovat, 410 Albany St, New Brunswick, NJ 08933 USA
[2] Johnson & Johnson, Vice Chairman Execut Comm, New Brunswick, NJ 08933 USA
[3] Johnson & Johnson, Chief Sci Officer Execut Comm, New Brunswick, NJ 08933 USA
关键词
D O I
10.1038/s41467-021-26103-3
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Partnerships between academic investigators and industry can accelerate the translation of research findings into life-saving products. The healthcare industry has witnessed heightened interest from universities in capitalizing on the discoveries made by faculty to create intellectual property, form new companies and seek investments. However, academic investigators and even Biotechnology start-ups may be unfamiliar with how industry sources and evaluates these opportunities. In this Comment, we share the approaches and principles by which a large healthcare company sources innovation and assesses opportunities to serve as a guide to better deal making with the goal of improving health for humanity.
引用
收藏
页数:4
相关论文
共 5 条
[1]  
[Anonymous], 2021, CAP MARK WATCH Q
[2]  
Belldegrun A, 2021, EMBR ENTR CANC RES A
[3]  
Feld Brad, 2019, VENTURE DEALS, V4th
[4]   Advancing development of medicines by academia and non-profit research organizations in the European Union [J].
Gonzalez-Quevedo, Rosa ;
Ziogas, Constantinos ;
Silva, Ivana ;
Vegter, Rosan ;
Humphreys, Anthony .
NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (04) :245-246
[5]   The cost of drug development: A systematic review [J].
Morgan, Steve ;
Grootendorst, Paul ;
Lexchin, Joel ;
Cunningham, Colleen ;
Greyson, Devon .
HEALTH POLICY, 2011, 100 (01) :4-17